Patents by Inventor Jacob Ulrik Fog

Jacob Ulrik Fog has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compstatin analogues and their medical uses
    Patent number: 11965039
    Abstract: Compstatin analogues having improved binding and complement-inhibiting activity as compared to the 13 amino acid compstatin peptide (ICVVQDWGHHRCT (cyclic C2-C12)) are described, in particular compstatin analogues that additionally possess useful physicochemical properties, such as increased solubility. These analogues include variants with an isoleucine residue at position 3 in place of the wild type valine residue, which provides compstatin peptides with improved binding and complement-inhibiting activity and also enables the introduction of other modifications, for example modifications that are capable of increasing solubility, such as the introduction of charged or polar amino acids at position 9 and/or the introduction of N- and/or C-terminal sequences.
    Type: Grant
    Filed: February 26, 2019
    Date of Patent: April 23, 2024
    Assignee: ZP SPV 3 K/S
    Inventors: Anne Pernille Tofteng Shelton, Jacob Ulrik Fog, Jens Kvist Madsen
  • GIP agonist compounds and methods
    Patent number: 11814417
    Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: November 14, 2023
    Assignee: Zealand Pharma A/S
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
  • Hepcidin analogues and uses thereof
    Patent number: 11807674
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: November 7, 2023
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • COMPSTATIN ANALOGUES AND THEIR MEDICAL USES
    Publication number: 20230192770
    Abstract: Compstatin analogues having improved binding and complement-inhibiting activity as compared to the 13 amino acid compstatin peptide (ICVVQDWGHHRCT (cyclic C2-C12)) are described, in particular compstatin analogues that additionally possess useful physicochemical properties, such as increased solubility. These analogues include variants with an isoleucine residue at position 3 in place of the wild type valine residue, which provides compstatin peptides with improved binding and complement-inhibiting activity and also enables the introduction of other modifications, for example modifications that are capable of increasing solubility, such as the introduction of charged or polar amino acids at position 9 and/or the introduction of N- and/or C-terminal sequences.
    Type: Application
    Filed: February 26, 2019
    Publication date: June 22, 2023
    Inventors: Anne Pernille Tofteng SHELTON, Jacob Ulrik FOG, Jens Kvist MADSEN
  • HEPCIDIN ANALOGUES AND USES THEREOF
    Publication number: 20220348626
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: November 16, 2020
    Publication date: November 3, 2022
    Inventors: Mark Leslie SMYTHE, Gregory Thomas BOURNE, Simone VINK, Brian Troy FREDERICK, Praveen MADALA, Anne Pernille TOFTENG SHELTON, Jacob Ulrik FOG
  • GIP AGONIST COMPOUNDS AND METHODS
    Publication number: 20220041676
    Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Application
    Filed: April 2, 2021
    Publication date: February 10, 2022
    Inventors: Anne Pernille Tofteng SHELTON, Pia NØRREGAARD, Maria Alexandrovna DERYABINA, Bjarne Due LARSEN, Jacob Ulrik FOG
  • GIP-GLP-1 dual agonist compounds and methods
    Patent number: 11008375
    Abstract: The present invention relates to acylated GIP analogues which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: August 27, 2018
    Date of Patent: May 18, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Jacob Ulrik Fog, Carsten Boye Knudsen
  • GIP agonist compounds and methods
    Patent number: 11001619
    Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: May 11, 2021
    Assignee: Zealand Pharma A/S
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
  • Hepcidin analogues and uses thereof
    Patent number: 10501515
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: December 10, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Hepcidin analogues and uses thereof
    Patent number: 10442846
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: October 15, 2019
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • GIP AGONIST COMPOUNDS AND METHODS
    Publication number: 20190256569
    Abstract: The present invention relates to acylated GIP analogues which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Application
    Filed: February 21, 2019
    Publication date: August 22, 2019
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
  • GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS
    Publication number: 20190218270
    Abstract: The present invention relates to acylated GIP analogues which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.
    Type: Application
    Filed: August 27, 2018
    Publication date: July 18, 2019
    Inventors: Anne Pernille Tofteng SHELTON, Pia NØRREGAARD, Jacob Ulrik FOG, Carsten Boye KNUDSEN
  • HEPCIDIN ANALOGUES AND USES THEROF
    Publication number: 20190185536
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: February 28, 2019
    Publication date: June 20, 2019
    Inventors: Mark Leslie SMYTHE, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • HEPCIDIN ANALOGUES AND USES THEREOF
    Publication number: 20190185535
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: July 17, 2018
    Publication date: June 20, 2019
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian Troy Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • GIP agonist compounds and methods
    Patent number: 10253078
    Abstract: The present invention relates to acylated GIP analogs which have GIP agonist activity, and their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: April 9, 2019
    Assignee: Zealand Pharma A/S
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Maria Alexandrovna Deryabina, Bjarne Due Larsen, Jacob Ulrik Fog
  • GIP-GLP-1 dual agonist compounds and methods
    Patent number: 10093713
    Abstract: The present invention relates to acylated GIP analogs which have dual GIP and GLP-1 activity, and their use in the treatment of metabolic disorders.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: October 9, 2018
    Assignee: Zealand Pharma A/S
    Inventors: Anne Pernille Tofteng Shelton, Pia Nørregaard, Jacob Ulrik Fog, Carsten Boye Knudsen
  • Hepcidin analogues and uses thereof
    Patent number: 10030061
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: July 24, 2018
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • HEPCIDIN ANALOGUES AND USES THEREOF
    Publication number: 20180100004
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: September 29, 2017
    Publication date: April 12, 2018
    Inventors: Mark Leslie Smythe, Gregory Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • HEPCIDIN ANALOGUES AND USES THEREOF
    Publication number: 20180086811
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Application
    Filed: November 30, 2017
    Publication date: March 29, 2018
    Inventors: Mark Leslie Smythe, Gregory Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog
  • Hepcidin analogues and uses thereof
    Patent number: 9822157
    Abstract: The present invention relates, inter alia, to certain hepcidin peptide analogs, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: November 21, 2017
    Assignee: Protagonist Therapeutics, Inc.
    Inventors: Mark Leslie Smythe, Gregory Thomas Bourne, Simone Vink, Brian T. Frederick, Praveen Madala, Anne Pernille Tofteng Shelton, Jacob Ulrik Fog